Alpha Cancer Technologies
Company Information
Alpha Cancer Technologies is a private clinical-stage biotechnology company developing platforms in immuno-oncology, radiopharmaceuticals, and immunomodulation. Its programs are built around a patented recombinant human alpha fetoprotein platform, or ACT-101, with development work spanning cancer and autoimmune disease applications. The company’s website describes IND-enabling work in radiopharmaceutical and immuno-oncology programs and a Phase II-ready immunomodulation program in myasthenia gravis.
Industry Focus and Technologies
Immuno-oncology, radiopharmaceuticals, immunomodulation, recombinant protein therapeutics, and clinical-stage biotechnology.
Location
Toronto, Ontario, Canada
Company Size and Stage
Products, Platforms or Focus Areas
Alpha fetoprotein platform technologies; ACT-101; immuno-oncology programs; radiopharmaceutical candidates including diagnostic and therapeutic isotopes; and immunomodulation programs for autoimmune disease.